Repligen Co. (RGEN) Holdings Trimmed by California Public Employees Retirement System

Share on StockTwits

California Public Employees Retirement System reduced its stake in shares of Repligen Co. (NASDAQ:RGEN) by 2.1% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 100,868 shares of the biotechnology company’s stock after selling 2,213 shares during the quarter. California Public Employees Retirement System’s holdings in Repligen were worth $5,320,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. American Capital Management Inc. grew its position in shares of Repligen by 1.4% in the fourth quarter. American Capital Management Inc. now owns 70,675 shares of the biotechnology company’s stock valued at $3,727,000 after purchasing an additional 960 shares during the last quarter. First Trust Advisors LP boosted its position in Repligen by 0.6% during the fourth quarter. First Trust Advisors LP now owns 69,603 shares of the biotechnology company’s stock worth $3,671,000 after acquiring an additional 422 shares during the last quarter. Prudential Financial Inc. boosted its position in Repligen by 173.4% during the fourth quarter. Prudential Financial Inc. now owns 197,400 shares of the biotechnology company’s stock worth $10,411,000 after acquiring an additional 125,195 shares during the last quarter. Piedmont Investment Advisors Inc. boosted its position in Repligen by 3.6% during the fourth quarter. Piedmont Investment Advisors Inc. now owns 9,289 shares of the biotechnology company’s stock worth $490,000 after acquiring an additional 319 shares during the last quarter. Finally, Westpac Banking Corp acquired a new stake in Repligen during the fourth quarter worth approximately $4,577,000. Institutional investors own 90.66% of the company’s stock.

In other Repligen news, CEO Anthony Hunt sold 13,000 shares of the stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $58.50, for a total transaction of $760,500.00. Following the transaction, the chief executive officer now owns 229,657 shares of the company’s stock, valued at $13,434,934.50. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, VP Ralf Kuriyel sold 2,240 shares of the stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $58.53, for a total transaction of $131,107.20. Following the transaction, the vice president now directly owns 21,043 shares in the company, valued at approximately $1,231,646.79. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 27,731 shares of company stock worth $1,625,768. 1.40% of the stock is currently owned by insiders.

NASDAQ:RGEN opened at $59.17 on Friday. The company has a market cap of $2.62 billion, a price-to-earnings ratio of 81.05, a P/E/G ratio of 4.07 and a beta of 1.09. Repligen Co. has a fifty-two week low of $34.05 and a fifty-two week high of $70.50.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Thursday, February 21st. The biotechnology company reported $0.21 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.21. The company had revenue of $51.90 million for the quarter, compared to the consensus estimate of $50.27 million. Repligen had a net margin of 8.56% and a return on equity of 5.51%. Repligen’s revenue was up 24.8% on a year-over-year basis. During the same quarter last year, the firm posted $0.20 earnings per share. As a group, equities analysts expect that Repligen Co. will post 0.83 EPS for the current year.

A number of analysts recently issued reports on the stock. Zacks Investment Research upgraded shares of Repligen from a “sell” rating to a “hold” rating in a research report on Wednesday, February 27th. BidaskClub lowered shares of Repligen from a “buy” rating to a “hold” rating in a research report on Wednesday, January 2nd. Finally, CL King upgraded shares of Repligen from a “neutral” rating to a “buy” rating in a research report on Monday, December 17th. They noted that the move was a valuation call. Four investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $59.20.

TRADEMARK VIOLATION NOTICE: “Repligen Co. (RGEN) Holdings Trimmed by California Public Employees Retirement System” was originally reported by Ticker Report and is owned by of Ticker Report. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece can be viewed at https://www.tickerreport.com/banking-finance/4222527/repligen-co-rgen-holdings-trimmed-by-california-public-employees-retirement-system.html.

Repligen Company Profile

Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process worldwide. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.

Featured Article: What are the benefits of a balanced fund?

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Co. (NASDAQ:RGEN).

Institutional Ownership by Quarter for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Haymaker Acquisition  Coverage Initiated at Jefferies Financial Group
Haymaker Acquisition Coverage Initiated at Jefferies Financial Group
Tilly’s  Given a $18.00 Price Target at B. Riley
Tilly’s Given a $18.00 Price Target at B. Riley
Analyzing MoSys  and Ameri
Analyzing MoSys and Ameri
Zacks: Analysts Expect Lipocine Inc  to Announce -$0.22 EPS
Zacks: Analysts Expect Lipocine Inc to Announce -$0.22 EPS
Baidu  Price Target Lowered to $160.00 at Barclays
Baidu Price Target Lowered to $160.00 at Barclays
EBOS Group  Reaches New 12-Month High at $21.50
EBOS Group Reaches New 12-Month High at $21.50


© 2006-2019 Ticker Report